| Literature DB >> 17383485 |
Christian J H Veillette1, Michael D McKee.
Abstract
Advances in the understanding of bone repair and improved biotechnology have led to the introduction of new strategies for orthopedic surgeons to control and modulate bone healing using growth factors. However, many orthopedic surgeons are uncertain about the current levels of evidence supporting the use of materials that possess these properties and their therapeutic role in the management of skeletal problems such as fracture, long-bone nonunion, and spine fusion. In particular, the differences amongst osteoinductive factors synthesized by recombinant gene technology, or derived from demineralized bone matrix or platelet rich plasma requires clarification.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17383485 DOI: 10.1016/j.injury.2007.02.009
Source DB: PubMed Journal: Injury ISSN: 0020-1383 Impact factor: 2.586